PCM
XENE icon

Prelude Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Prelude Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,266
Closed -$613K – 1412
2025
Q1 		$613K Hold
18,266
– – 0.05% 444
2024
Q4 		$716K Hold
18,266
– – 0.04% 473
2024
Q3 		$719K Sell
18,266
-69
-0.4% -$2.78K 0.04% 484
2024
Q2 		$715K Buy
18,335
+24
+0.1% +$959 0.05% 393
2024
Q1 		$788K Sell
18,311
-13,885
-43% -$639K 0.04% 461
2023
Q4 		$1.48M Buy
32,196
+16,438
+104% +$581K 0.1% 228
2023
Q3 		$538K Buy
15,758
+286
+2% +$10.7K 0.04% 453
2023
Q2 		$596K Sell
15,472
-6,540
-30% -$260K 0.04% 409
2023
Q1 		$788K Buy
22,012
+9,243
+72% +$341K 0.05% 353
2022
Q4 		$503K Buy
+12,769
New +$465K 0.03% 569
2017
Q3 		– Sell
-738
Closed -$2K – 1935
2017
Q2 		$2K Buy
+738
New +$2.88K ﹤0.01% 1533
2017
Q1 		– Sell
-34,928
Closed -$269K – 1816
2016
Q4 		$269K Buy
+34,928
New +$280K 0.03% 472
2015
Q3 		– Sell
-2,600
Closed -$30K – 1839
2015
Q2 		$30K Buy
2,600
+1,600
+160% +$22.1K ﹤0.01% 1276
2015
Q1 		$17K Buy
+1,000
New +$18.5K ﹤0.01% 1771

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Prelude Capital Management's XENE Position: Q2 2025 in Review

Prelude Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2025, closing a stake of 18,266 shares — an estimated $613K sold.

Prelude Capital Management first reported a position in XENE in Q1 2015 and held it in 14 quarters. The position peaked at $1.48M in Q4 2023. 206 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

  • Prelude Capital Management reported no remaining Xenon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Prelude Capital Management sold 18,266 Xenon Pharmaceuticals shares in Q2 2025, an estimated $613K.
  • Prelude Capital Management first reported a position in Xenon Pharmaceuticals in Q1 2015 and held it in 14 quarters.
  • Prelude Capital Management's Xenon Pharmaceuticals position peaked at $1.48M in Q4 2023.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.